Seres Therapeutics to Present at the Canaccord Genuity 37th Annual Growth Conference

CAMBRIDGE, Mass.--()--Seres Therapeutics, Inc. (NASDAQ:MCRB) today announced it will present at the Canaccord Genuity 37th Annual Growth Conference in Boston, MA on Wednesday, August 9 at 1:00 p.m. ET.

A live audio webcast of the presentation will be available under the “Investors and Media” section of Seres’ website. A replay of the presentation will become available approximately one hour after the event and will be archived for 21 days.

About Seres Therapeutics

Seres Therapeutics, Inc., is a leading microbiome therapeutics platform company developing a novel class of biological drugs that are designed to treat disease by restoring the function of a dysbiotic microbiome, where the natural state of bacterial diversity and function is imbalanced. Seres’ lead program, SER-109, has obtained Breakthrough and Orphan Drug designations from the U.S. Food and Drug Administration and is in Phase 3 development for multiply recurrent C. difficile infection. Seres’ clinical candidate SER-287 is being evaluated in a Phase 1b study in patients with mild-to-moderate ulcerative colitis. Seres is also developing SER-262, the first ever synthetic microbiome therapeutic candidate, in a Phase 1b study in patients with primary C. difficile infection. For more information, please visit www.serestherapeutics.com. Follow us on Twitter @SeresTx.

Contacts

IR or PR Contact:
Seres Therapeutics
Carlo Tanzi, Ph.D., 617-203-3467
Head of Investor Relations and Corporate Communications
Ctanzi@serestherapeutics.com

Release Summary

Seres Therapeutics, Inc. today announced it will present at the Canaccord Genuity 37th Annual Growth Conference in Boston, MA on August 9, 2017.

Contacts

IR or PR Contact:
Seres Therapeutics
Carlo Tanzi, Ph.D., 617-203-3467
Head of Investor Relations and Corporate Communications
Ctanzi@serestherapeutics.com